Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Freeline Therapeutics Holdings Plc Adss (FRLN)

Freeline Therapeutics Holdings Plc Adss (FRLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Thu Aug 4, 2022

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted...

FRLN : 6.48 (unch)
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress Globe Newswire - Sun Jul 10, 2022

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON,...

FRLN : 6.48 (unch)
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Fri Jul 1, 2022

LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a...

FRLN : 6.48 (unch)
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress Globe Newswire - Fri Jun 24, 2022

LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and...

FRLN : 6.48 (unch)
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B Globe Newswire - Tue Jun 14, 2022

Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same...

FRLN : 6.48 (unch)
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Fri Jun 3, 2022

LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its...

FRLN : 6.48 (unch)
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Globe Newswire - Fri Jun 3, 2022

LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of...

FRLN : 6.48 (unch)
Freeline Reports First Quarter 2022 Financial Results and Business Highlights Globe Newswire - Tue May 10, 2022

Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief...

FRLN : 6.48 (unch)
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Tue May 3, 2022

LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April...

FRLN : 6.48 (unch)
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy Globe Newswire - Mon May 2, 2022

Five abstracts accepted with new research and technology insights and data to further enhance AAV-based gene therapy candidates...

FRLN : 6.48 (unch)

Barchart Exclusives

Will Meta Platforms Stock Be Worth $2 Trillion in 2025? Barchart - 4 minutes ago
Meta stock reached a new all-time high of $617.78, propelling the company’s market capitalization to approximately $1.55 trillion. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot